$455 million: Philanthropist Stephen Schwarzman’s Blackstone backs a miniature heart pump and puts capital where his philanthropy has long pointed
Some of the most dangerous moments in cardiac medicine happen after the heart attack itself.
Sometimes the damaged heart can no longer move enough blood to keep the brain, kidneys, and other organs supplied with oxygen.
Doctors call this cardiogenic shock, and close to half of these patients do not survive.
Now Blackstone, the firm Stephen Schwarzman co-founded and still leads, committed up to $455 million to help Boston Scientific build a device meant to change those odds.
The device is called VITALYST.
It is a next-generation, miniature heart pump that is inserted through a catheter rather than through open-heart surgery, and it is designed to keep blood moving to the brain and vital organs while the heart recovers.
The money comes from Blackstone Life Sciences, the firm’s $18 billion medical investing arm. It is the first time the two companies have jointly funded the development of a Boston Scientific product.
Blackstone shares the cost of development and, if the pump clears regulators and reaches patients, can receive milestone payments of up to 2.5 times its contribution, plus royalties on sales.
Still, it is hard to read the announcement without thinking of the man whose name is on so many buildings.
Over the past two decades, Schwarzman has given away more than $1 billion.
Nearly every one of those gifts follows a single conviction: that big ideas need big, permanent institutions behind them.
His $100 million gift to the New York Public Library put his name on its Fifth Avenue flagship.
He then founded Schwarzman Scholars at Tsinghua University in Beijing, a Rhodes-style fellowship that has grown into a program worth more than $575 million.
At Yale, his alma mater, he gave $150 million to turn the historic Commons into a new kind of student center.
He also gave $40 million to the Inner-City Scholarship Fund so that low-income children could attend Catholic schools in New York.
His gifts then turned toward the future. In 2018 he gave $350 million to found the MIT Schwarzman College of Computing, which reorganized one of the world’s great technical universities around artificial intelligence.
At Oxford, a gift that grew to £185 million built the Schwarzman Centre for the Humanities.
It brings all of the university’s humanities faculties under one roof for the first time and houses an Institute for Ethics in AI, and King Charles III formally opened it this summer.
In 2020 Schwarzman signed the Giving Pledge, committing the majority of his wealth to philanthropy.
That is where the heart pump fits into the larger story. Earlier this year, Schwarzman’s plans to give the “substantial majority” of his fortune, estimated at more than $40 billion, to the Stephen A. Schwarzman Foundation became public.
The foundation is expected to keep focusing on four areas: education, culture, the impact of artificial intelligence, and medical innovation.
If it is funded at that scale, it could one day be larger than every American foundation except Gates and Lilly.
His philanthropy has built the places where ideas are developed.
His firm is now paying for the slow, expensive work of turning one idea into a device a surgeon can use at two in the morning.
The bet is a serious one.
Boston Scientific chief executive Mike Mahoney has called VITALYST “the largest investment we have in the company.”
The company also changed the pump’s first major trial to focus on heart attack patients in shock.
It made that change after the DanGer Shock trial showed that a rival pump, Johnson & Johnson’s Impella, reduced deaths in this group from 58.5 percent to 45.8 percent at six months, though with more bleeding and vascular complications.
VITALYST is designed with those risks in mind. Its magnetically driven impeller may be gentler on blood vessels, and its catheter and motor are built to stay steady inside the heart and to protect red blood cells.
A pivotal study is expected to begin in 2027, with a launch targeted around 2030. The pump has not been approved.
“We believe the VITALYST system has the potential to improve on the efficacy and safety of currently available mechanical circulatory support technologies,” said Nicholas Galakatos, global head of Blackstone Life Sciences.
He said the partnership reflects the firm’s ability “to help leaders in innovation bring important new medical devices to patients.”
At 79, Schwarzman has spent a career turning capital into institutions and institutions into legacy.
His gifts have shaped how students learn, how scholars think, and how the next generation will live with artificial intelligence.
This latest commitment works differently.
It is designed to earn a return, and we will measure its success in the hours it buys for patients in shock.
